Raptor Pharmaceutical Corp. (NASDAQ:RPTP) was upgraded by stock analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, The Fly reports.

An institutional investor recently raised its position in Raptor Pharmaceutical Corp. stock. Birchview Capital increased its stake in shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) by 17.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The hedge fund owned 54,000 shares of the company’s stock after buying an additional 8,000 shares during the period. Birchview Capital’s holdings in Raptor Pharmaceutical Corp. were worth $327,000 as of its most recent filing with the SEC.

Several other equities research analysts have also commented on RPTP. Wedbush restated a “neutral” rating and issued a $7.00 price objective on shares of Raptor Pharmaceutical Corp. in a research note on Thursday, December 10th. Oppenheimer restated a “hold” rating on shares of Raptor Pharmaceutical Corp. in a research note on Tuesday, December 1st. Zacks Investment Research upgraded Raptor Pharmaceutical Corp. from a “sell” rating to a “hold” rating in a research note on Monday, October 12th. Finally, Leerink Swann restated an “outperform” rating on shares of Raptor Pharmaceutical Corp. in a research note on Tuesday, October 6th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Raptor Pharmaceutical Corp. presently has a consensus rating of “Buy” and an average target price of $14.50.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) traded up 2.63% during trading on Tuesday, reaching $3.90. The company had a trading volume of 3,111,125 shares. The firm’s 50 day moving average price is $4.52 and its 200 day moving average price is $8.11. The firm’s market capitalization is $331.89 million. Raptor Pharmaceutical Corp. has a 12-month low of $2.94 and a 12-month high of $16.28.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.18) EPS for the quarter, hitting the consensus estimate of ($0.18). The company earned $25.80 million during the quarter, compared to analysts’ expectations of $24.25 million. The company’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter last year, the company earned ($0.04) earnings per share. Analysts anticipate that Raptor Pharmaceutical Corp. will post ($0.78) earnings per share for the current year.

Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company’s product, PROCYSBI delayed-release capsules received marketing approval from the FDA for the management of nephropathic cystinosis in adults and children six years and older. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine, received a marketing authorization from the European Commission (NASDAQ:RPTP), as an orphan medicinal product for the management of nephropathic cystinosis in the European Union (EU). The Company’s pipeline includes its delayed-release form of cysteamine, or RP103 and its oral 4-methylpyrazole, or Convivia. Its other product, Quinsair, is an inhaled formulation of levofloxacin used for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

12 Month Chart for NASDAQ:RPTP

The Fly

Receive News & Ratings for Raptor Pharmaceutical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raptor Pharmaceutical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.